UNSPSC 51273305: Euprocin hydrochloride

This classification denotes an anesthetic agent C24H34N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EVA0339N2N, chemically known as cinchonan-9-ol, 10,11-dihydro-6'-(3-methylbutoxy)-, dihydrochloride, (8.alpha.,9r)-, but more generally known as euprocin hydrochloride, which bears US NIH Compound Identifier 68544. Most nations, for tariff and trade purposes, schedule euprocin hydrochloride under HS 29392000 and SITC 54142. As of Q4 2014, EUPROCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Euprocin hydrochloride bears US NLM identifiers UMLS ID C2700027 and NCI Concept Code C75096. SMILES: CC[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@@H](C3CCNC4C3CC(CC4)OCCC(C)C)O.CL.CL.

UNSPSC 51273305 Euprocin hydrochloride is a Commodity code that nominally names a specific pharmaceutical active ingredient, but recent state and local solicitations show little alignment with this narrow chemical specification. The three most recent opportunities posted under this code involve naloxone procurement, a direct-to-manufacturer prescription program request for information, and a multi-state cooperative purchasing agreement for generic pharmaceuticals and over-the-counter products — none of which target euprocin specifically. State and local governments do procure pharmaceuticals and medical supplies through competitive solicitation, but the tagging of these opportunities under a Commodity code for a single active ingredient suggests either systematic miscoding by issuing offices or a gap between the UNSPSC taxonomy and how jurisdictions actually purchase drugs in bulk.

The issuing bodies include a Florida county health department (Seminole County), a state health agency (Texas Health and Human Services Commission), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, administered by Minnesota Department of Administration, serving Oregon and other participating jurisdictions). The geographic footprint spans Florida, Texas, Minnesota, and Oregon based on recent postings. Recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2023; Texas HHS's RFI on direct-to-manufacturer prescription programs posted April 3, 2026; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026. The code shows no current relevant activity aligned with euprocin procurement; prospecting under this code for pharmaceutical supply contracts will require validating the actual scope against jurisdictional solicitations rather than assuming the code name predicts the content.